gemcitabine + nab-paclitaxel + radiation therapy

This neoadjuvant treatment regimen is being evaluated by the University of Florida in the GAIN-1 Phase II clinical trial for patients with resectable or borderline-resectable pancreatic adenocarcinoma. The regimen consists of systemic chemotherapy using gemcitabine and nab-paclitaxel (Abraxane), followed by chemoradiotherapy (radiation therapy combined with chemotherapy) for high-risk or borderline-resectable cases prior to surgical resection. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while nab-paclitaxel is an albumin-bound nanoparticle formulation of paclitaxel that disrupts microtubule dynamics. The addition of radiation therapy aims to improve local control and increase the likelihood of achieving negative surgical margins (R0 resection).

Brand names

AbraxaneGemzar

Other names

Gemcitabine + Abraxane + ChemoradiotherapyChemotherapy + Chemoradiotherapy-University of Florida-pancreatic adenocarcinoma